Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025
Lipocine (NASDAQ: LPCN) has announced that two abstracts for their drug candidate LPCN 2101, being developed for epilepsy treatment, have been accepted for poster presentation at the 2025 American Epilepsy Society (AES) annual meeting in Atlanta, Georgia, December 5-9.
The presentations will focus on the oral toxicokinetics and clinical pharmacokinetics of LPCN 2101, a GABA A receptor modulating neuroactive steroid. The first presentation is scheduled for December 7, and the second for December 8, 2025. The abstracts are currently under embargo until November 24, 2025.
Lipocine (NASDAQ: LPCN) ha annunciato che due abstract relativi al candidato farmaco LPCN 2101, sviluppato per il trattamento dell'epilessia, sono stati accettati per una presentazione poster al Congress annuale 2025 della American Epilepsy Society (AES) ad Atlanta, Georgia, dal 5 al 9 dicembre.
Le comunicazioni verteranno sulla tossicocinetica orale e sulla farmacocinetica clinica di LPCN 2101, uno steroide neuroattivo che modula il recettore GABA A. La prima presentazione 猫 prevista per il 7 dicembre e la seconda per l'8 dicembre 2025. Gli abstract sono attualmente sotto embargo fino al 24 novembre 2025.
Lipocine (NASDAQ: LPCN) ha anunciado que dos res煤menes sobre su candidato farmacol贸gico LPCN 2101, desarrollado para el tratamiento de la epilepsia, han sido aceptados para su presentaci贸n en p贸ster en la reuni贸n anual 2025 de la American Epilepsy Society (AES) en Atlanta, Georgia, del 5 al 9 de diciembre.
Las presentaciones se centrar谩n en la toxicocin茅tica oral y la farmacocin茅tica cl铆nica de LPCN 2101, un esteroide neuroactivo modulador del receptor GABA A. La primera presentaci贸n est谩 programada para el 7 de diciembre y la segunda para el 8 de diciembre de 2025. Los res煤menes est谩n actualmente bajo embargo hasta el 24 de noviembre de 2025.
Lipocine (NASDAQ: LPCN)鞚� 臧勳 旃橂毳� 鞙勴暣 臧滊皽 欷戩澑 鞎诫 頉勲炒 LPCN 2101鞐� 甏�頃� 霊� 韼胳潣 齑堧鞚� 2025雲� 12鞗� 5鞚茧秬韯� 9鞚缄箤歆� 臁办鞎勳＜ 鞎犿媭霝滍儉鞐愳劀 鞐措Μ電� 氙戈淡 臧勳頃欗殞(AES) 鞐半須岇潣 2025 韽姢韯� 氚滍憸搿� 毂勴儩霅橃棃雼り碃 氚滍憸頄堨姷雼堧嫟.
氚滍憸電� GABA A 靾橃毄觳措ゼ 臁办爤頃橂姅 鞁犼步頇滌劚 鞀ろ厡搿滌澊霌滌澑 LPCN 2101鞚� 瓴疥惮 霃呾劚霃欗儨頃欔臣 鞛勳儊 鞎诫彊頃欖棎 齑堨爯鞚� 毵烄稖 鞓堨爼鞛呺媹雼�. 觳� 氚滍憸電� 2025雲� 12鞗� 7鞚�, 霊� 氩堨Ц 氚滍憸電� 12鞗� 8鞚检棎 鞓堨爼霅橃柎 鞛堨姷雼堧嫟. 齑堧鞚� 順勳灛 2025雲� 11鞗� 24鞚缄箤歆� 氤措弰 旮堨 靸來儨鞛呺媹雼�.
Lipocine (NASDAQ: LPCN) a annonc茅 que deux r茅sum茅s concernant leur candidat-m茅dicament LPCN 2101, d茅velopp茅 pour le traitement de l'茅pilepsie, ont 茅t茅 accept茅s pour une pr茅sentation par poster lors de la r茅union annuelle 2025 de l'American Epilepsy Society (AES) 脿 Atlanta, G茅orgie, du 5 au 9 d茅cembre.
Les pr茅sentations porteront sur la toxicocin茅tique orale et la pharmacocin茅tique clinique de LPCN 2101, un st茅ro茂de neuroactif modulant le r茅cepteur GABA A. La premi猫re pr茅sentation est pr茅vue le 7 d茅cembre et la seconde le 8 d茅cembre 2025. Les r茅sum茅s sont actuellement sous embargo jusqu'au 24 novembre 2025.
Lipocine (NASDAQ: LPCN) hat bekanntgegeben, dass zwei Abstracts zu ihrem Wirkstoffkandidaten LPCN 2101, der zur Behandlung von Epilepsie entwickelt wird, zur Posterpr盲sentation auf der Jahrestagung 2025 der American Epilepsy Society (AES) in Atlanta, Georgia, vom 5. bis 9. Dezember akzeptiert wurden.
Die Beitr盲ge befassen sich mit der oralen Toxikokinetik und der klinischen Pharmakokinetik von LPCN 2101, einem neuroaktiven Steroid, das den GABA-A-Rezeptor moduliert. Die erste Pr盲sentation ist f眉r den 7. Dezember geplant, die zweite f眉r den 8. Dezember 2025. Die Abstracts stehen derzeit bis zum 24. November 2025 unter Embargo.
- None.
- None.
AES 2025 Annual Meeting: December 5-9, 2025听 听 | |
Title:听 听 | Oral Toxicokinetics of a Bioidentical GABAA Receptor Modulating |
Author:听 听 | Joshua C.听Weavil, Jonathan Ogle, Min-Jee Goh, Joel Frank, Samuel Akapo, |
Date:听听 | Sunday, December 7, 12:00 PM 鈥� 2:00 PM |
Abstract Number:听 听 | 2.331 |
Title:听 听 | Clinical Pharmacokinetics (PK) and Tolerability of a Novel Oral GABAA听 |
Author:听 | Min-Jee Goh, Jonathan Ogle, Joshua C. Weavil, Joel Frank, Samuel Akapo, |
Date:听 听 | Monday, December 8, 2025, 12:00 PM 鈥� 1:45 PM |
Abstract Number:听 | 3.354 |
Abstracts are embargoed from the AES online abstract database until Monday, November 24, 2025.
About Lipocine
Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent听enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.
Lipocine's clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of epilepsy, LPCN 2203 an oral candidate targeted for the management of essential tremor, LPCN 2401 an oral proprietary anabolic androgen receptor agonist, as an adjunct therapy to incretin mimetics, as an aid for improved body composition in obesity management and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 for obesity management, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, our candidate for treatment of metabolic dysfunction-associated steatohepatitis (MASH). TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit听www.lipocine.com.
View original content to download multimedia:
SOURCE Lipocine Inc.
FAQ
When and where will Lipocine (LPCN) present its LPCN 2101 abstracts at AES 2025?
What is LPCN 2101 being developed for by Lipocine?
What topics will be covered in Lipocine's AES 2025 presentations?
When will the Lipocine (LPCN) AES 2025 abstracts become publicly available?
